Literature DB >> 9332903

Treatment of schizophrenia and delusional disorder in the elderly.

J H Eastham1, D V Jeste.   

Abstract

With increasing longevity, greater numbers of patients with schizophrenia and delusional disorder will be surviving into advanced age. Antipsychotics form the core of the treatment for both of these psychotic disorders. Treatment of elderly patients with antipsychotics is, however, complicated by a much higher risk of adverse effects such as tardive dyskinesia. More is known about treating patients with schizophrenia than those with delusional disorder. The introduction of newer atypical antipsychotics may herald a new era in the pharmacotherapy of elderly psychotic patients. Nonetheless, judicious dosing is essential in the geriatric population. We discuss the benefits and limitations of the main forms of treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9332903     DOI: 10.1007/bf02900217

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  55 in total

1.  Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium.

Authors:  L Tune; S Carr; E Hoag; T Cooper
Journal:  Am J Psychiatry       Date:  1992-10       Impact factor: 18.112

2.  A clinical and neuropsychological comparison of delusional disorder and schizophrenia.

Authors:  J D Evans; J S Paulsen; M J Harris; R K Heaton; D V Jeste
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1996       Impact factor: 2.198

3.  Treatment of resistant schizophrenia with valproate and neuroleptic drugs.

Authors:  A Moriñigo; J Martin; S Gonzalez; I Mateo
Journal:  Hillside J Clin Psychiatry       Date:  1989

Review 4.  Ethnicity and movement disorders.

Authors:  J H Eastham; J P Lacro; D V Jeste
Journal:  Mt Sinai J Med       Date:  1996 Oct-Nov

5.  Can schizophrenia begin after age 44?

Authors:  P Rabins; S Pauker; J Thomas
Journal:  Compr Psychiatry       Date:  1984 May-Jun       Impact factor: 3.735

6.  The effect of age and thioridazine on the in vitro binding of fluphenazine to normal human serum.

Authors:  F J Rowell; S M Hui; A F Fairbairn; D Eccleston
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

7.  Catamnestic long-term study on the course of life and aging of schizophrenics.

Authors:  L Ciompi
Journal:  Schizophr Bull       Date:  1980       Impact factor: 9.306

8.  Clozapine in the elderly.

Authors:  F R Frankenburg; D Kalunian
Journal:  J Geriatr Psychiatry Neurol       Date:  1994 Apr-Jun       Impact factor: 2.680

Review 9.  Drug treatment as a cause of falls in old age. A review of the offending agents.

Authors:  A J Campbell
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

10.  Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

Authors:  D V Jeste; M P Caligiuri; J S Paulsen; R K Heaton; J P Lacro; M J Harris; A Bailey; R L Fell; L A McAdams
Journal:  Arch Gen Psychiatry       Date:  1995-09
View more
  4 in total

Review 1.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Erotomania : epidemiology and management.

Authors:  Brendan D Kelly
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Quetiapine: a review of its safety in the management of schizophrenia.

Authors:  V Dev; J Raniwalla
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

4.  A Perspective on the Primary Care of Patients With Behavior, Mood, and Thought Disturbances: Clinical Applications of Olanzapine.

Authors:  Donald P. Hay; Daniel J. Hurley; Hillary C. McGuire; Linda K. Hay
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.